Effects of Intrauterine Administration of Autologous PBMC on the Endometrial Cells Populations

NCT05421364 | Recruiting

• 1 other identifier: 10/12042022
• Study Type: interventional
• Target: 300
• Locations: 1 country
• Sites: 2

Brief Summary

The behaviour of the endometrium during its receptive phase is highly dependent on the endometrial cell type composition. Each cell type has its role in the endometrial preparation for the invading embryo. Alteration in the immune cells dialogue could be the main reason for unsuccessful implantation in certain patients. Immune cell homeostasis is often improved by intrauterine administration of autologous PBMC. There have been numerous reports on the positive effects of the intrauterine administration of autologous PBMC on the IVF outcomes (embryo implantation and ongoing pregnancy success). However, there is little data on the direct effect of the PBMC administration on the cell composition of the endometrium. This study will focus on the changes in the endometrial cell populations by PBMC treatment that could lead to IVF outcome improvement. The aim of this project is to analyze the effect of intrauterine administration of autologous PBMC on the endometrial cell populations and on the IVF outcome parameters (implantation and ongoing pregnancy success as IVF outcome variables).

Conditions

Female Infertility

Keywords

Peripheral blood mononuclear cells (PBMC); Female infertility; Endometrium; Endometrial cell populations

Outcome Measures

Primary Outcomes (3)

• Change in the numbers of certain ednometrial cell populations (immune cells, stem cells, senescent cells) from their levels one month prior intrauterine PBMC administration

  Immunohistochemical analysis

  One month following intrauterine PBMC administration

• Change in the percentages of the immune cells in the endometrial stroma from their levels one month prior intrauterine PBMC administration

  Flowcytometric analysis

  One month following intrauterine PBMC administration

• Change in the distance between the endometrial immune cells, stem cells and senescent cells in the endometrial stroma from their initial distances one month prior intrauterine PBMC administration

  Spatial analysis with Visual analysis software

  One month following intrauterine PBMC administration

Secondary Outcomes (2)

• Embryo implantation rate

  Two weeks following embryo transfer

• Clinical pregnancy rate

  Six to 8 weeks of gestation

Study Arms (1)

Endometrial cell composition

EXPERIMENTAL

The cell composition and their quantities will be compared before and after intrauterine administration of PBMC in the endometrial biopsies.

Biological: Intrauterine administration of autologous peripheral blood mononuclear cells (PBMC)

Interventions

Intrauterine administration of autologous peripheral blood mononuclear cells (PBMC) BIOLOGICAL

Approximately 9 ml blood from each patient will be collected on the day of the LH peak by peripheral venipuncture using a 21G butterfly catheter affixed via vacutainer to negative pressure receiving tubes (BD vacutainer acid-citrate-dextrose (ACD-A), REF:366645). PBMC will be isolated by density gradient centrifugation in room-temperature centrifuge set to 400 g for 25 min. PBMCs (1x106cells/ml) suspended in RPMI 1640 supplemented with 10% HSA will be incubated in the presence of 10 IU/ml hHCG for 48 h. On day 2 after LH peak, fresh PBMCs (1x107 cells) will be also obtained from the same patients, these fresh PBMCs will be immediately combined with the 2-day cultured PBMC and suspended in PBS (2x107 cells/200µl). This cell suspension will be carefully introduced in the uterine cavity by catheter on day 2 after LH peak.

Endometrial cell composition

Eligibility Criteria

• Age: 20 Years - 50 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Participating in Assisted Reproduction Treatment
• Presenting altered endometrial immune profile
• Having primary infertility
• Having regular menstrual cycles
• Embryo transfer of euploid embryos

You may not qualify if:

• Uterine pathologies
• Endometrial Bacterial infections
• Active endometrial inflammation
• Polycystic ovary syndrome
• Presence of auto anti-bodies such as anti-TPO, anti-TG, ACA, APA, ANA, and anti-dsDNA
• Presence of mutations involving the coagulation system such as deficiency of factor XII, Pro C, Pro S
• Cancer diagnostics
• Positive HIV, HCV or HBV tests

Sponsors & Collaborators

• Nadezhda Women's Health Hospital: lead
• Medical diagnostic laboratory ImunoVita: collaborator

Study Sites (2)

Nadezhda Women's Health Hospital

Sofia, Sofia, 1373, Bulgaria

RECRUITING

Medical diagnostic laboratory Imunovita

Sofia, 1373, Bulgaria

RECRUITING

MeSH Terms

Conditions

Infertility, Female

Condition Hierarchy (Ancestors)

Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases; Infertility

Central Study Contacts

Georgi Stamenov, MD

CONTACT

+359888269839; g.stamenov@abv.bg

Rumiana Ganeva, MSc

CONTACT

+359898484825; rum.ganeva@gmail.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: Both prior to and following PBMC treatment endometrial biopsies will be obtained on day 7 after LH peak. The endometrial samples will be stained immunohistochemically with antibodies against specific endometrial cell types.The endometrial cell composition and the specific cell types quantities will be evaluated by microscopic observation and flowcytometric analysis. The cell composition and their quantities will be compared before and after intrauterine administration of PBMC in the endometrial biopsies.

Study Record Dates

• First Submitted: June 6, 2022
• First Posted: June 16, 2022
• Study Start: December 9, 2023
• Primary Completion: January 3, 2026
• Study Completion (Estimated): December 9, 2026
• Last Updated: May 21, 2025

Record last verified: 2025-05

Data Sharing

• IPD Sharing: Will not share

Locations

BU (2)